While the mechanism of action behind HDAC inhibitors in PAH and RV remodeling has not yet been fully elucidated, unraveling it might help in achieving more specific therapies for the both PAH and RV failure (RVF). The gene discussed is HDAC9; the disease is pulmonary arterial hypertension.